NCT01814670View on ClinicalTrials.gov

Treatment With Botulinum Toxin Type A (BOTOX®) in Chinese Patients With Moderate to Severe Frown Lines

PHASE4CompletedINTERVENTIONAL
Enrollment

185

Participants

Timeline

Start Date

March 6, 2013

Primary Completion Date

July 31, 2014

Study Completion Date

October 29, 2014

Conditions
Glabellar Rhytides
Interventions
BIOLOGICAL

botulinum toxin Type A

20 units botulinum toxin Type A (total dose) injected into frown lines on Day 1.

Trial Locations (1)

Unknown

Beijing

Sponsors

Lead Sponsor

Allergan
All Listed Sponsors
lead

Allergan

INDUSTRY

NCT01814670 - Treatment With Botulinum Toxin Type A (BOTOX®) in Chinese Patients With Moderate to Severe Frown Lines | Biotech Hunter | Biotech Hunter